Wednesday's Bio-Pharma Catalyst Trades And Watch List
November 21, 2012
I think it's a good bet Sarepta gets the early approval, which would likely cause the stock price to explode from its current price level of $27 a share -- I can easily see a stock price approaching $75 or higher here.
DMD is a very rare disease that affects mainly children -- a potential cure for any form of MD would be on par with Jonas Salk's discovery of the Polio vaccine in my strong opinion.
Between the 5 analysts that cover the stock, the mean price target is a whopping $44.20.